131 related articles for article (PubMed ID: 25641680)
1. 5'-Ectonucleotidase/CD73 expression on lymph-circulating lymphocytes and lymphatic endothelial cells offers new paths to explore barrier function.
Sidibé A; Imhof BA
Eur J Immunol; 2015 Feb; 45(2):371-5. PubMed ID: 25641680
[TBL] [Abstract][Full Text] [Related]
2. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.
Yegutkin GG; Auvinen K; Rantakari P; Hollmén M; Karikoski M; Grénman R; Elima K; Jalkanen S; Salmi M
Eur J Immunol; 2015 Feb; 45(2):562-73. PubMed ID: 25402681
[TBL] [Abstract][Full Text] [Related]
3. Different role of CD73 in leukocyte trafficking via blood and lymph vessels.
Ålgars A; Karikoski M; Yegutkin GG; Stoitzner P; Niemelä J; Salmi M; Jalkanen S
Blood; 2011 Apr; 117(16):4387-93. PubMed ID: 21346249
[TBL] [Abstract][Full Text] [Related]
4. Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function.
Narravula S; Lennon PF; Mueller BU; Colgan SP
J Immunol; 2000 Nov; 165(9):5262-8. PubMed ID: 11046060
[TBL] [Abstract][Full Text] [Related]
5. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes.
Takedachi M; Qu D; Ebisuno Y; Oohara H; Joachims ML; McGee ST; Maeda E; McEver RP; Tanaka T; Miyasaka M; Murakami S; Krahn T; Blackburn MR; Thompson LF
J Immunol; 2008 May; 180(9):6288-96. PubMed ID: 18424752
[TBL] [Abstract][Full Text] [Related]
6. IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation.
Niemelä J; Henttinen T; Yegutkin GG; Airas L; Kujari AM; Rajala P; Jalkanen S
J Immunol; 2004 Feb; 172(3):1646-53. PubMed ID: 14734746
[TBL] [Abstract][Full Text] [Related]
7. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
[TBL] [Abstract][Full Text] [Related]
8. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism.
Airas L; Niemelä J; Jalkanen S
J Immunol; 2000 Nov; 165(10):5411-7. PubMed ID: 11067892
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells.
Airas L; Niemelä J; Salmi M; Puurunen T; Smith DJ; Jalkanen S
J Cell Biol; 1997 Jan; 136(2):421-31. PubMed ID: 9015312
[TBL] [Abstract][Full Text] [Related]
10. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73.
Airas L; Hellman J; Salmi M; Bono P; Puurunen T; Smith DJ; Jalkanen S
J Exp Med; 1995 Nov; 182(5):1603-8. PubMed ID: 7595232
[TBL] [Abstract][Full Text] [Related]
11. Complex regulation of ecto-5'-nucleotidase/CD73 and A
Nedeljkovic N
Pharmacol Res; 2019 Jun; 144():99-115. PubMed ID: 30954629
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation.
Lennon PF; Taylor CT; Stahl GL; Colgan SP
J Exp Med; 1998 Oct; 188(8):1433-43. PubMed ID: 9782120
[TBL] [Abstract][Full Text] [Related]
13. The role of ecto-5'-nucleotidase in endothelial dysfunction and vascular pathologies.
Zukowska P; Kutryb-Zajac B; Toczek M; Smolenski RT; Slominska EM
Pharmacol Rep; 2015 Aug; 67(4):675-81. PubMed ID: 26321267
[TBL] [Abstract][Full Text] [Related]
14. Adenosine Formed by CD73 on T Cells Inhibits Cardiac Inflammation and Fibrosis and Preserves Contractile Function in Transverse Aortic Constriction-Induced Heart Failure.
Quast C; Alter C; Ding Z; Borg N; Schrader J
Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28404626
[TBL] [Abstract][Full Text] [Related]
15. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
16. CD73: a potent suppressor of antitumor immune responses.
Beavis PA; Stagg J; Darcy PK; Smyth MJ
Trends Immunol; 2012 May; 33(5):231-7. PubMed ID: 22487321
[TBL] [Abstract][Full Text] [Related]
17. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
18. Targeting the CD73-adenosine axis in immuno-oncology.
Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
[TBL] [Abstract][Full Text] [Related]
19. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier.
Niemelä J; Ifergan I; Yegutkin GG; Jalkanen S; Prat A; Airas L
Eur J Immunol; 2008 Oct; 38(10):2718-26. PubMed ID: 18825744
[TBL] [Abstract][Full Text] [Related]
20. Dengue virus type 2 modulates endothelial barrier function through CD73.
Patkar C; Giaya K; Libraty DH
Am J Trop Med Hyg; 2013 Jan; 88(1):89-94. PubMed ID: 23149581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
